SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
MDGL
--
0.00%
--
3 Top Biotech Stocks to Buy in June
Motley Fool · 4h ago
BMO Capital Initiates Coverage On Madrigal Pharmaceuticals with Market Perform Rating, Announces Price Target of $135
BMO Capital analyst Matthew Luchini initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Perform rating and announces Price Target of $135.
Benzinga · 1d ago
We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Simply Wall St. · 05/28 13:07
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 11:25
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 118 companies set new 52-week highs.
Benzinga · 05/26 14:32
Stocks That Hit 52-Week Highs On Friday
On Friday, 46 stocks hit new 52-week highs.
Benzinga · 05/22 14:31
10 Biggest Price Target Changes For Friday
Barclays boosted L Brands Inc (NYSE: LB) price target from $10 to $17. L Brands closed at $14.45 on Thursday.
Benzinga · 05/22 12:06
B. Riley FBR Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $174
B. Riley FBR maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $134 to $174.
Benzinga · 05/22 10:46
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 120 stocks hit new 52-week highs.
Benzinga · 05/18 14:44
After Drug Failure, Genfit's Cupboard Is Nearly Bare
GuruFocus.com · 05/14 22:31
Biotech Stock Rally Is Crushing Short Sellers
Benzinga’s Take Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development. Shorting these types of stocks can be very risky due to the potential for unexpec
Benzinga · 05/11 16:15
Was The Smart Money Right About Madrigal Pharmaceuticals (MDGL)?
Insider Monkey · 05/10 20:18
H.C. Wainwright Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $168
H.C. Wainwright maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $215 to $168.
Benzinga · 05/08 15:47
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
GlobeNewswire · 05/07 11:50
Madrigal Pharmaceuticals Q1 EPS $(2.340) Down From $(0.980) YoY
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(2.340) per share. This is a 138.78 percent decrease over losses of $(0.980) per share from the same period last year.
Benzinga · 05/07 10:51
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGL
ACCESSWIRE · 05/05 16:00
Benzinga's Top Upgrades, Downgrades For May 5, 2020
Upgrades
Benzinga · 05/05 13:35
Chardan Capital Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target to $205
Chardan Capital analyst Michael Morabito initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target to $205.
Benzinga · 05/05 10:25
Madrigal Pharma up 13% on positive data on NASH drug resmetirom
seekingalpha · 04/14 18:09